Ecovyst Q3 2026 Earnings: Sales Rise 51% as Adjusted EBITDA Margin Narrows
Ecovyst reported Q3 2026 sales of $308.6 million, up 50.6% year-over-year, driven by the Calabrian acquisition, higher volumes, pricing, and sulfur-cost pass-through. However, rising input costs and inflation narrowed margins, with adjusted EBITDA rising 6.4% to $61.2 million and diluted EPS reaching $0.17. Following operating momentum and a deferred turnaround, the company raised its full-year 2026 guidance, projecting sales of $1.05 billion to $1.07 billion and adjusted EBITDA of $208 million to $212 million. Key risks include margin pressure, leverage rising to 2.1x, sulfur-price volatility, and integration of Calabrian.
Ecovyst (NYSE: ECVT) reported Q3 2026 sales of $308.6 million, up 50.6% from $204.9 million, while diluted EPS from continuing operations rose to $0.17 from $0.00. Adjusted EBITDA increased 6.4% to $61.2 million, as the first full quarter of Calabrian ownership, higher sulfuric acid volumes, and favorable pricing lifted sales, but cost pass-through and higher operating expenses narrowed margins. The quarter ended September 30, 2026.
Key Results
All comparative operating results below refer to continuing operations because the Advanced Materials & Catalysts business, sold on December 31, 2025, is classified as discontinued operations. Revenue benefited from higher volumes and pricing, the Calabrian acquisition, and approximately $67 million of sulfur-cost pass-through, while manufacturing, inflation, and transportation costs limited profit growth. The increase in GAAP net income also reflected a lower tax provision of $4.5 million versus $20.2 million a year earlier.
| Metric (USD millions, except per-share data) | Q3 2026 | Q3 2025 | YoY Change |
|---|---|---|---|
| Sales | $308.6 | $204.9 | +50.6% |
| Gross profit / margin | $58.7 / approx. 19.0% | $52.1 / approx. 25.4% | +12.7%; margin -6.4 pts |
| Operating income / margin | $29.2 / approx. 9.5% | $28.3 / approx. 13.8% | +3.2%; margin -4.3 pts |
| Net income from continuing operations | $18.4 | $0.2 | NM |
| Diluted EPS from continuing operations | $0.17 | $0.00 | NM |
| Adjusted net income | $25.3 | $21.5 | Approx. +17.7% |
| Adjusted diluted EPS | $0.23 | $0.19 | Approx. +21.1% |
| Adjusted EBITDA / margin | $61.2 / 19.8% | $57.5 / 28.1% | +6.4%; margin -8.3 pts |
NM means the percentage comparison is not meaningful because of the small prior-year base.
Revenue Growth Outpaced Profit Growth as Cost Pass-Through Diluted Margins
Sales increased by $103.7 million, but roughly $67 million—or about 65% of that increase—came from passing higher sulfur costs through to customers. Because this portion represents cost pass-through, it should be viewed alongside higher sulfur input costs rather than as equivalent underlying profit growth.
That dynamic helps explain why gross profit increased by only $6.6 million and operating income by $0.9 million despite the much larger sales gain. Adjusted EBITDA margin fell from 28.1% to 19.8%, with higher manufacturing costs, general inflation, and transportation expenses adding further pressure.
Business and Product Performance
Regenerated sulfuric acid volumes and sales increased due to strong refining margins, higher export demand, and less customer downtime. Management expects high refinery utilization and alkylate demand to continue supporting this business through year-end, although unplanned refinery outages remain a potential source of volatility.
Virgin sulfuric acid sales benefited from demand for mining applications, stable industrial demand, and favorable pricing. Management expects continued copper-mining demand to support sales, but cautioned that a significant decrease in sulfur prices could lead customers to reduce inventories temporarily.
Calabrian, acquired on June 30, 2026, contributed for a full quarter for the first time. The business added sulfur dioxide and related derivatives exposure, including demand from Canadian gold mines, but Ecovyst did not disclose separate Q3 sales or adjusted EBITDA for Calabrian.
Cash Flow and Balance Sheet
For the nine months ended September 30, cash flow from continuing operations increased to $80.7 million from $77.0 million. However, total operating cash flow, including discontinued operations, fell to $76.5 million from $98.5 million, while purchases of property, plant, and equipment increased to $72.7 million from $67.1 million on the adjusted free-cash-flow basis. As a result, adjusted free cash flow declined to $32.4 million from $42.4 million.
Ecovyst ended the quarter with $71.2 million in cash, $497.1 million of gross debt, and $425.9 million of net debt. The net debt leverage ratio rose to 2.1x from 1.2x at the end of 2025, primarily because the company added $100 million to its term loan for the Calabrian acquisition while only one quarter of Calabrian adjusted EBITDA was included in the trailing twelve-month calculation. Available liquidity totaled $167.0 million, including $95.8 million under the asset-based lending facility.
2026 Guidance
Ecovyst raised its full-year outlook following its first-nine-month performance and the movement of a planned turnaround from Q4 2026 into early 2027. The higher outlook therefore reflects both operating momentum and a timing benefit from the deferred turnaround.
| Metric | Latest 2026 Guidance | Previous Guidance | Change |
|---|---|---|---|
| Sales | $1.05 billion-$1.07 billion | $1.02 billion-$1.06 billion | Range raised |
| Adjusted EBITDA | $208 million-$212 million | $195 million-$207 million | Range raised |
| Adjusted free cash flow | $50 million-$60 million | $45 million-$55 million | Range raised |
| Capital expenditures | $90 million-$95 million | $85 million-$95 million | Lower end raised |
| Adjusted net income | $70 million-$85 million | $65 million-$85 million | Lower end raised |
| Adjusted diluted EPS | $0.63-$0.77 | $0.58-$0.72 | Range raised |
The sales outlook assumes approximately $220 million of sulfur-cost pass-through for the full year. The adjusted EBITDA range includes an expected Q4 contribution of $5 million to $6 million from Calabrian.
Recent Insider Transactions
Recent reported insider activity included one purchase and one sale among the latest transactions. These transactions are presented objectively and do not, by themselves, establish insiders’ views of Ecovyst’s outlook.
| Date | Insider | Role | Transaction | Price per Share | Value |
|---|---|---|---|---|---|
| September 10, 2026 | Patti A. Humble | Director | Purchase | $10.05 | $249,994 |
| June 2, 2026 | Sarah J. Lorance | Director | Sale | $13.33 | $112,638 |
Risks Investors Should Monitor
- Margin pressure: Reported sales are growing much faster than gross profit and adjusted EBITDA, partly because sulfur-cost pass-through raises both revenue and costs. Manufacturing, inflation, and transportation expenses could create additional pressure.
- Refinery outages: Unplanned customer downtime could reduce regenerated sulfuric acid volumes, even if broader refinery utilization remains high.
- Sulfur-price volatility: A significant decline in sulfur prices could prompt near-term customer destocking and reduce reported sales tied to cost pass-through.
- Acquisition and leverage exposure: Realizing Calabrian synergies depends on successful integration, while acquisition financing has already increased net debt and leverage.
- Cash conversion: Adjusted free cash flow declined through the first nine months despite higher continuing-operations earnings, and the lower end of capital expenditure guidance was raised.
Summary
Ecovyst’s Q3 2026 results combined acquisition- and volume-driven sales growth with substantially slower profit expansion and lower margins. Calabrian, refining demand, mining demand, and pricing supported the top line, while sulfur-cost pass-through and higher operating costs limited EBITDA growth. The raised full-year outlook is constructive for the remaining quarter, but margin trends, cash conversion, refinery uptime, Calabrian integration, and the higher leverage profile remain the main issues to monitor.
This article may include AI-generated content that is human-reviewed, which is for reference and general information purposes only and does not constitute investment advice.
Recommended Articles









Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.